A Third Shot at EGFR: New Opportunities in Cancer Therapy.
EGF inhibitors
EGFR
biological drugs
drug resistance
oncology
targeted drugs
Journal
Trends in pharmacological sciences
ISSN: 1873-3735
Titre abrégé: Trends Pharmacol Sci
Pays: England
ID NLM: 7906158
Informations de publication
Date de publication:
12 2019
12 2019
Historique:
received:
16
04
2019
revised:
11
10
2019
accepted:
15
10
2019
pubmed:
11
11
2019
medline:
14
7
2020
entrez:
11
11
2019
Statut:
ppublish
Résumé
Epidermal growth factor receptor (EGFR) inhibitors were among the first type of targeted agents discovered in cancer and currently constitute the standard of care for a wide range of lung and colon malignancies. However, the therapeutic progress achieved with these drugs has been accompanied by the identification of an ever-increasing number of acquired resistance mechanisms that inevitably appear in nearly all patients. Increased knowledge on EGFR biochemistry, cellular crosstalk, and resistance pathways provides an opportunity to establish effective combination therapies and discover novel-acting inhibitors that prevent or overcome therapeutic resistance. One such strategy is the selective blockade of circulating growth factors such as EGF. In this review, we address the uses and limitations of approved EGFR inhibitors and explore the potential of drug combinations and new third avenues to block the activation of the EGFR.
Identifiants
pubmed: 31706618
pii: S0165-6147(19)30230-5
doi: 10.1016/j.tips.2019.10.004
pii:
doi:
Substances chimiques
Protein Kinase Inhibitors
0
Epidermal Growth Factor
62229-50-9
EGFR protein, human
EC 2.7.10.1
ErbB Receptors
EC 2.7.10.1
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
941-955Informations de copyright
Copyright © 2019 Elsevier Ltd. All rights reserved.